Hydroxyurea Treatment for Sickle Cell Disease
High fetal hemoglobin (HbF) levels inhibit the polymerization of sickle hemoglobin (HbS) and reduce the complications of sickle cell disease. Pharmacologic agents that can reverse the switch from γ- to β-chain synthesis — γ-globin chains characterize HbF, and sickle β-globin chains are present in Hb...
Saved in:
Main Author: | Martin H. Steinberg |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2002-01-01
|
Series: | The Scientific World Journal |
Online Access: | http://dx.doi.org/10.1100/tsw.2002.295 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Nutritional Evaluation of Pediatric Patients with Sickle Cell Disease Treated with Hydroxyurea
by: Belkis Lázara Rodríguez Jorge, et al.
Published: (2021-03-01) -
Impact of hydroxyurea on clinical and biological parameters of sickle cell anemia in children in Abidjan
by: MIREILLE YAYO- AYE, et al.
Published: (2024-02-01) -
Sickle Cell Anemia, the First Molecular Disease: Overview of Molecular Etiology, Pathophysiology, and Therapeutic Approaches
by: Martin H. Steinberg
Published: (2008-01-01) -
Morphine for the Treatment of Pain in Sickle Cell Disease
by: Mihir Gupta, et al.
Published: (2015-01-01) -
Asthma in Sickle Cell Disease: Implications for Treatment
by: Kathryn Blake, et al.
Published: (2011-01-01)